This iShares ETF Beats Its Mid-Cap Rival on Price -- but Not on Stability

ISCV is materially cheaper than IJJ, with a 0.06% expense ratio versus 0.18%, while also offering a higher trailing-12-month return of 34.10% versus 26.50% and a slightly higher dividend yield of 1.90% versus 1.70%. IJJ, however, has much larger AUM at $8.5 billion versus $644.8 million and a smaller 5-year drawdown at (22.70%) versus (25.30%). The article is a comparative ETF analysis rather than a catalyst-driven event, so the likely market impact is limited.

Analysis

The cleaner read is not “small-cap vs mid-cap,” but fee drag versus implementation quality. ISCV’s lower cost means it only needs to avoid roughly 12-15 bps of annual underperformance versus IJJ to win over a multi-year horizon, yet its deeper drawdown history suggests the extra return is being paid for with materially worse left-tail risk. In other words, ISCV is the more aggressive cyclical beta sleeve; IJJ is the more stable cashflow compounder, and that distinction matters most when growth expectations roll over.

The holdings mix implies different second-order beneficiaries. IJJ’s heavier exposure to industrials and financials should outperform in a soft-landing / late-cycle regime where credit stays orderly and capex holds up; ISCV’s smaller, more fragmented names are more exposed to financing conditions and end-demand shocks, so it likely underperforms first if spreads widen or PMI data reaccelerate downward. The small-cap fund’s broader diversification reduces single-name idiosyncratic risk, but it does not eliminate factor risk: in stress, liquidity and balance-sheet quality dominate, and that is where mid-caps historically hold up better.

The market is probably over-anchoring on the trailing 12-month performance gap and underpricing regime sensitivity. A small-cap value basket can keep outperforming for months if rates drift lower and the dollar softens, but the setup is fragile if economic data cools faster than earnings estimates are reset. Conversely, if industrial activity stabilizes and financials avoid credit deterioration, IJJ’s higher fee can still be justified by lower drawdown and better capital preservation.

The one name-level nuance is Moderna inside ISCV: its presence can inject biotech-style volatility into a value wrapper, which can distort the fund’s realized risk profile versus what a pure value investor expects. That makes ISCV less clean as a defensive value allocation and more of a cyclical-plus-event-risk basket.

Key Decisions for Investors

• Prefer IJJ over ISCV for core value exposure over the next 3-6 months if the base case is slowing growth with sticky financing conditions; the tradeoff is ~12 bps of higher fee for meaningfully better drawdown control.
• Use ISCV only as a tactical pro-cyclical expression for a 6-12 month reflation / rate-cut continuation view; size smaller than IJJ due to higher tail risk and historical drawdown depth.
• Pair trade: long IJJ / short ISCV on a 1-2 month horizon if credit spreads start widening or if macro data weaken; this isolates quality/liquidity premium and should work best in risk-off tape.
• If you want small-cap beta, hedge ISCV with short XLI or financials exposure rather than selling the ETF outright; the fund’s factor mix is most vulnerable to industrial and financing slowdowns.
• Avoid overcommitting to trailing winners in either ETF; wait for a 5-10% pullback in the sleeve you prefer before adding, since these value factors can mean-revert quickly when positioning gets crowded.